Living

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

By Reuters Reuters
FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Dado Ruvic Reuters

AbbVie will acquire biotech Apogee Therapeutics for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 22, 2026 at 6:04 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER